Altai Protocol Library
1041 protocols and counting
All protocols with references and links
All protocols reviewed by a Medical Oncologist/Hematologist
All protocols in major guidelines included
Ability to create your own protocols
New Indication: Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA)
Study: Open-label, multicentre, phase 3 study Untreated CLL or SLL Patients without del (17) (p13·1) zanubrutinib (group A; n=241) or bendamustine–rituximab (group B; n=238) and patients with del(17) (p13·1)
New Indication: Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312)
Study: Open-label, randomised, phase 3 trial Previously untreated advanced hepatocellular carcinoma Cabozantinib 40 mg plus atezolizumab 1200 mg IV every 3 weeks (N:432), sorafenib 400 mg twice Daily (n:217), or
New Indication: Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312)
Study: Open-label, randomised, phase 3 trial Previously untreated advanced hepatocellular carcinoma Cabozantinib 40 mg plus atezolizumab 1200 mg IV every 3 weeks (N:432), sorafenib 400 mg twice Daily (n:217), or
New Reference: Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
Study: Phase 3, randomized, double-blind, international trial Previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer Pembrolizumab (200 mg every 3 weeks) plus chemotherapy (n:566) or chemotherapy (n:281) Efficacy:
New Reference: Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
Study: Phase 3, randomized, double-blind, international trial Previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer Pembrolizumab (200 mg every 3 weeks) plus chemotherapy (n:566) or chemotherapy (n:281) Efficacy:
New Indication: Crizotinib for ALK-positive inflammatory myofibroblastic tumor
Study: Multicenter, single‐arm, open‐label phase 1b study (PROFILE 1013) ALK‐positive advanced malignancies other NSCLC (N:44) Crizotinib 250 mg x 2 /day Efficacy: ORR: 53% (95% CI, 28-77), CR:8/18 and PR:1/18
New Indication: Trastuzumab deruxtecan for her2+ NSCLC
Study: Multicenter, international, phase 2 study Metastatic HER2-mutant NSCLC (refractory to standard treatment) Trastuzumab deruxtecan >= 6.4 mg per kilogram of body weight Efficacy: ORR: 55% (95% CI, 44 to
New Indication: Trastuzumab deruxtecan for her2+ NSCLC
Study: Multicenter, international, phase 2 study Metastatic HER2-mutant NSCLC (refractory to standard treatment) Trastuzumab deruxtecan >= 6.4 mg per kilogram of body weight Efficacy: ORR: 55% (95% CI, 44 to
New Indication: Atezolizumab for early-stage NSCLC
Study: Open-label Phase III trial (IMpower010) Completely resected early-stage NSCLC s/p adjuvant platinum-based chemo Atezolizumab 1200 q21 x 1 yr vs. best supportive care Efficacy: Among pts with stage II-IIIA
New Indication: Atezolizumab for early-stage NSCLC
Study: Open-label Phase III trial (IMpower010) Completely resected early-stage NSCLC s/p adjuvant platinum-based chemo Atezolizumab 1200 q21 x 1 yr vs. best supportive care Efficacy: Among pts with stage II-IIIA
New Drug: Mobocertinib for EGFR Exon 20 insertion NSCLC
Study: Open-label Phase I/II trial (EXCLAIM) EGFR EX20ins+ metastatic NSCLC with >=1 prior line of therapy, platinum-pretreated (n=114) Mobocertinib 160 mg PO daily Efficacy: ORR: 28%, Disease control rate: 78%